Fat Accumulation Inhibitor and Method of Use Thereof
The present disclosure relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a fat accumulation inhibitor for a fat cell which includes a milk-derived phospholipid as an active ingredient to the subject. The present disclosure also relates to a method of inhibiting a visceral fat accumulation in a subject, which includes administering the visceral fat accumulation inhibitor which includes a sphingosine-containing phospholipid as an active ingredient to the subject. The present disclosure also relates to a method of accelerating increase and/or inhibiting decrease of an adiponectin concentration in blood, which includes administering an agent which includes a sphingosine-containing phospholipid as an active ingredient to the blood. The present disclosure also relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a milk-derived phospholipid to a subject.
1 - 14 . (canceled)
15 . A method of inhibiting a fat accumulation for a fat cell in a subject, which comprises administering a fat accumulation inhibitor for a fat cell which comprises a milk-derived phospholipid as an active ingredient to the subject.
16 . The method according to claim 15 , wherein the fat accumulation inhibitor comprises an effective amount of a milk-derived phospholipid composition for inhibiting fat accumulation,
wherein the milk-derived phospholipid composition comprises a lipid in an amount of from 20 to 90% by mass based on the total composition, and a phospholipid in an amount of from 40 to 55% by mass based on the total lipid.
17 . The method according to claim 15 , wherein the milk-derived phospholipid composition comprises an ash in an amount of at least 7% by mass based on the total composition.
18 . The method according to claim 15 , wherein the milk-derived phospholipid-containing composition is derived from a milk material.
19 . The method according to claim 18 , wherein the milk-derived phospholipid-containing composition is obtained by treating a milk or milk material with a microfiltration (MF) membrane having a pore size of from 0.1 to 2.0 μm or with an ultrafiltration (UF) membrane having a fractionating molecular weight of from 5 to 500 kDa.
20 . The method according to claim 18 , wherein the milk-derived phospholipid-containing composition is obtained by adjusting a milk or milk material to pH of 4.0 to 5.0 by adding an acid, thereby removing a casein protein as a precipitate, and then treating with an MF membrane having a pore size of from 0.1 to 2.0 μm or with a UF membrane having a fractionating molecular weight of from 5 to 500 kDa.
21 . The method according to claim 18 , wherein the milk or milk material is a butter serum or a butter milk.
22 . A method of inhibiting a visceral fat accumulation in a subject, which comprises administering the visceral fat accumulation inhibitor which comprises a sphingosine-containing phospholipid as an active ingredient to the subject.
23 . The method according to claim 22 , wherein the visceral fat accumulation inhibitor comprises an effective amount of a sphingosine-containing phospholipid composition comprising sphingomyelin in an amount of at least 95% by mass based on the total composition.
24 . The method according to claim 23 , wherein the sphingosine-containing phospholipid composition is derived from a milk material.
25 . The method according to claim 22 , wherein the sphingosine-containing phospholipid is sphingomyelin.
26 . A method of accelerating increase and/or inhibiting decrease of an adiponectin concentration in blood, which comprises administering an agent which comprises a sphingosine-containing phospholipid as an active ingredient to the blood.
27 . The method according to claim 26 , wherein the agent comprises an effective amount of a sphingosine-containing phospholipid composition comprising a sphingomyeline in an amount of at least 95% by mass based on the total agent.
28 . The method according to claim 27 , wherein the sphingosine-containing phospholipid composition is derived from a milk material.
29 . The method according to claim 26 , wherein the sphingosine-containing phospholipid is sphingomyelin.
30 . A method of inhibiting a fat accumulation for a fat cell in a subject, which comprises administering a milk-derived phospholipid to a subject.
31 . The method of claim 30 , wherein the phospholipid is obtained by
treating a milk or milk material with a microfiltration (MF) membrane having a pore size of from 0.1 to 2.0 μm or with an ultrafiltration (UF) membrane having a fractionating molecular weight of from 5 to 500 kDa to obtain a milk-derived phospholipid.
32 . The method of claim 31 , wherein the phospholipid is obtained by
removing a casein protein as a precipitate by adjusting a milk or milk material to pH of 4.0 to 5.0 by adding an acid prior to the treatment with the MF membrane or UF membrane.
33 . The method of claim 30 , wherein the phospholipid is derived from butter serum or a butter milk.